Study identifies factors that predict driving cessation in seniors
May 22, 2024
Older age, female sex and progression to symptomatic Alzheimer’s disease were associated with driving cessation.
Nearly 7 million Americans have Alzheimer’s, and caregivers are stressed
Mar 20, 2024
Nearly 7 million American seniors are living with Alzheimer’s dementia, placing a huge strain on both personal caregivers and the US healthcare system, according to a new Alzheimer’s Association...
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Allopurinol may cut risk for neurodegenerative diseases
May 19, 2023
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
Benefit of thick liquids in Alzheimer’s disease and dysphagia unclear
May 06, 2024
Patients receiving thick versus thin liquids were less likely to be intubated and more likely to have respiratory complications.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
17 percent of patients seeing neurologist travel long distance
Sep 13, 2023
Factors associated with long-distance travel include low neurologist density, rural setting and visits for ALS and nervous system cancer.
Vascular risk factors only explain part of Alzheimer’s disease risk for Blacks, Hispanics
Jan 11, 2023
Barriers to healthcare access and other socioeconomic factors may increase vulnerability in racial/ethnic minorities.
Gut microbial taxonomic profiles differ with, without preclinical Alzheimer’s disease
Jun 16, 2023
A change in gut microbiome composition was associated with β-amyloid and tau pathological brain biomarkers.
Lecanemab reduced markers of amyloid in early Alzheimer’s disease
Dec 01, 2022
Moderately less decline was seen in cognition and function at 18 months with lecanemab versus placebo.